Drug Discovery World

FEBRUARY 23, 2023

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need. The disease gets progressively worse, causing severe disability within three to five years of onset.

Drugs 52

Drugs Licensing Licensing Protein 52

Drug Discovery World

MAY 29, 2024

Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers’ and sellers’ goals. Does one side strongly desire an asset purchase or acquisition, while the other side prefers a co-development or co-commercialisation transaction?

Scientist 59

Scientist Licensing Licensing Development 59

BioTech 365

SEPTEMBER 21, 2021

Didier Landais as Chief Operating Officer LabGenius Appoints Dr. Didier Landais as Chief Operating Officer With over 30 years of industry experience, the former Global Head of Licensing at Servier Group will spearhead LabGenius’ business development, commercial … Continue reading →

Licensing 52

Licensing Licensing Business Development Development 52

Camargo

SEPTEMBER 23, 2020

Thomas Kassberg, Chief Business Officer, Ultragenyx. Thomas Kassberg, Chief Business Officer, Ultragenyx. I think you really need to get the feedback directly from patients and then incorporate that feedback as you think about how you’re going to develop the product to be successful. Tom Kassberg, Ultragenyx. Dan Curran, Takeda.

Business Development 136

Business Development Drugs Development Production 136

The Pharma Data

NOVEMBER 23, 2020

Berkien will join Ultimovacs from his current position at Amgen as Director Global Business Development. At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In

Business Development 52

Business Development Clinical Trials Clinical Trials Licensing 52

pharmaphorum

JANUARY 11, 2022

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by licensing up to four cancer cell therapy candidates from Century Therapeutics.

Clinical Trials 96

Clinical Trials Clinical Trials Licensing Licensing 96

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Market-maturity combined with demonstrated manufacturing scalability will drive the development and has the potential to accelerate the path to the clinic of Bayer and AskBio’s first in vivo gene editing programs.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. ” .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. ” Mr. Earlier in his career, he ran business-development functions at Amgen and Baxter.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

pharmaphorum

SEPTEMBER 8, 2020

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech. The latest partnerships are with Swiss startup NBE-Therapeutics and Catalent Pharma, and boost Exelixis’ ADC capabilities in multiple areas.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Business Development Genome Genomics 52

WCG Clinical

APRIL 3, 2023

Individual subscriptions , customized multi-user, and company licenses to FDAnews are also available. Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.

Compliance 52

Compliance Drugs Manufacturing Regulation 52

Drug Discovery World

NOVEMBER 10, 2023

AH : I am Chief Business Officer for Antibody Analytics, a collaborative immunology CRO, specialising in supporting immunotherapy developers at the discovery to pre-clinical stages of the drug development process. I loved being a part of something unique, exciting and closer to patients. New T cell targets (e.g.

Antibody 59

Antibody Clinical Trials Clinical Trials Life Science 59

Drug Discovery World

JANUARY 30, 2024

Natalia Elizalde, Chief Business Development Officer, VIVEbiotech, says that Dr Naldini’s award represents the significant benefits and demonstrated safety of the therapies developed using lentiviral vectors that are being used for more and more clinical trials and more prevalent diseases.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

pharmaphorum

MAY 18, 2022

The US pharma group is paying $47 million in upfront payments to license rights to the undisclosed drug outside China, Hong Kong, Macao, and Taiwan, with another $1.36 billion in potential milestone payments plus royalties on sales. Kelun Pharma said that the deal would accelerate its entry into international markets.

Drugs 57

Drugs Antibody Licensing Licensing 57

pharmaphorum

SEPTEMBER 28, 2022

Roche’s Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech’s programmable T cell-based therapies platform. Both companies will use the fruits of their collaboration in the development of future therapeutic candidates, said ArsenalBio in a statement.

Gene Editing 57

Gene Editing Genome Genomics Engineer 57

Drug Discovery World

JANUARY 23, 2024

Hardiman, Senior Director, Ventures – Business Development at Astellas, weighed in: “You’ve got to be intentional and creative to raise funds. As an R&D pipeline and business develops in an increasingly multi-disciplinary sector, new competencies are required to progress.

Life Science 59

Life Science Business Development Protein Development 59

Pharmaceutical Technology

FEBRUARY 16, 2023

Technology trends in the analysis, and test and measurement equipment industry The pharmaceutical industry is witnessing the need for software upgradation for research and development (R&D), and high-end communication technologies.

Engineer 130

Engineer Manufacturing Containment Production 130

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Also in December, the company partnered with Atara Biotherapeutics to develop off-the-shelf T-cell immunotherapies for high mesothelin-expressing tumors. Photo courtesy of Bayer. We have set the bar high.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

DECEMBER 14, 2022

One of the fund’s latest investments is in Extend, a new joint venture between Evotec, CDP Venture Capital, and Angelini Ventures which will leverage the best of scientific research from Italian academic institutions to support the development and commercialisation of promising therapeutics. About the interviewees.

Life Science 104

Life Science Development Business Development Genetics 104

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. She joined the Novartis COVID-19 R&D Task Force to help tackle the emerging pandemic, taking the reins of the business development workstream.

Business Development 52

Business Development Licensing Licensing Development 52

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases.

Immune Response 57

Immune Response Antibody Drugs Licensing 57

The Pharma Data

JANUARY 17, 2021

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. SPR206 is in clinical development as an innovative option for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. SHANGHAI , Jan. SHANGHAI , Jan. ” About SPR206.

Medicine 52

Medicine Clinical Development Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 15, 2020

The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. BeyondSpring – BeyondSpring Inc.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. NEW YORK and LONDON, Jan. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

AUGUST 17, 2021

An experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.

Medicine 52

Medicine Dermatology Production Development 52

The Pharma Data

NOVEMBER 3, 2020

According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA).

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Sigilon Therapeutics

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

JULY 29, 2021

Research and development expenses increased 30% to $3.3 billion in the quarter primarily due to higher license and asset acquisition charges and an in-process research and development (IPR&D) impairment charge. On a non-GAAP basis, research and development expenses increased 4% to $2.3 and Non-GAAP EPS of $1.93

Production 52

Production Sales Development Licensing 52

pharmaphorum

NOVEMBER 15, 2022

Smith shared this approach, remarking that 4BIO Capital takes a collaborative approach to invest, working closely with the founders and companies to develop a shared vision for growth. The panel began by addressing the difficulties companies can encounter in creating new out-licensing agreements and spinning out assets to form new companies.

Life Science 89

Life Science Pharma Companies Marketing Production 89

Drug Discovery World

SEPTEMBER 16, 2022

W here globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? There are a number of areas in the UK which are recognised as hubs for developers the sector. The UK stands as one of the key markets for cell and gene therapies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

NOVEMBER 8, 2020

We have done this by both internal talent development as well as by external hires. Our strategy is clear, and we are well positioned for a period of sustained growth of our core business over the coming years. Investment in Research & Development remained at c. Normalized net income was €74.2

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. “We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies. on a non-GAAP basis.

Antibody 52

Antibody Sales Production Development 52

The Pharma Data

NOVEMBER 25, 2020

Shafi Khan , Burkhan World’s VP of Business Development stated, “Burkhan is honoured to have partnered up with Vivera in supporting its efforts globally in the medical supply sector. With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. ,

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Manufacturing Licensing 52

The Pharma Data

NOVEMBER 10, 2020

Furthermore, data show that the class of drug substances being developed within AlzeCure’s platform, so-called gamma-secretory modulators, selectively affect the production of toxic Abeta-amyloid, without affecting the cleavage of other substrates that potentially play an important role in normal physiological function. in the brain.

Development 40

Development Drugs Protein Research 40